Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Key Factors Distinguish Transient Post-Stroke Symptoms

Published: Tue, 15 Aug 2017 14:38:27 EDT
Investigators have identified key risk factors, triggers, and clinical features of transient post-stroke recrudescence in findings that may help clinicians distinguish this phenomenon from new stroke symptoms.
Medscape Medical News

New Anti-VEGF Drug Promising for Wet Macular Degeneration

Published: Tue, 15 Aug 2017 14:16:11 EDT
OPT-302, a new vascular endothelial growth factor (VEGF) inhibitor, appears to be safe and shows signs it could slow the progression of neovascular age-related macular degeneration.
Medscape Medical News

Noninvasive Method May Tell Alzheimer's From FTD

Published: Tue, 15 Aug 2017 13:37:42 EDT
A new method using transcranial magnetic stimulation may help differentiate Alzheimer's disease from frontotemporal dementia, new research shows.
Medscape Medical News

NAMS' Hormone Therapy Statement: Primary Care Takeaways

Published: Tue, 15 Aug 2017 12:43:14 EDT
Who can safely take hormone therapy and for how long? Are there alternatives? Dr JoAnn Manson answers questions based on the new position statement from the North American Menopause Society.
Medscape Internal Medicine
Displaying results 17-20 (of 20)
 1 - 2 - 3 - 4 - 5 


Celgene drops Sutro buyout option and refocuses deal on 4 I-O programs, freeing partner to pursue new alliances, IPO

Published: Thu, 10 Aug 2017 07:16:35 +0000
Celgene and Sutro Biopharma have revised the terms of the immuno-oncology pact they entered into in 2014. The reshuffle sees Celgene secure a stake in four assets that are advancing toward the clinic and opportunities to invest in Sutro at the expense of its option to buy the biotech outright.

Testing the safety of immunotherapy in diabetes

Published: Wed, 09 Aug 2017 18:05:59 +0000
Researchers have long been interested in using immunotherapy techniques to tamp down diabetes, but they’ve worried that they’ll accidentally make the disease worse. Now, researchers in the U.K. are describing a treatment that has proven safe and effective in a small trial.

CRUK, Biotecnol team up for T-cell engager trial

Published: Wed, 09 Aug 2017 15:55:51 +0000
Biotecnol has teamed up with Cancer Research UK (CRUK) to take its T-cell engager into the clinic. The agreement sees CRUK take a stake in the Anglo-Portuguese biotech in return for help testing a 5T4-CD3 bispecific antibody in patients with lung cancer and other solid tumors.

Melinta merges with faltering Cempra, bagging a Nasdaq listing and a pipeline of anti-infective programs

Published: Wed, 09 Aug 2017 13:23:08 +0000
Melinta Therapeutics has struck a deal to merge with Cempra. The agreement brings together two of the biotechs plugging away, with mixed success, at late-phase development of anti-infective drugs.
Displaying results 21-24 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy